XCancer

CXCR4 PET/MRI Targeted Imaging for Grading Diagnosis, Molecular Typing, and Prognostic Evaluation of Brain Glioma

Description:

This project intends to evaluate the role of C-X-C chemokine receptor type 4 (CXCR4) targeted PET/MRI integrated imaging in the grading and molecular typing of brain gliomas, using primary glioma patients as the research subjects and post-operative histopathological analysis as the reference, and to establish an evaluation model for the prognosis of primary glioma patients.

Sponsor:

Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Contacts:

Du ZHenwei, Ph.D (CONTACT)

peter11dzw@126.com

+8618580503880

Chen Xiao, Ph.D (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT06234319 - Click here to see study on

ClinicalTrials.gov

PSMA-11

Isotope(s):
Target(s):
  • CXCR4
Ligand Class: Small Molecules
Chelator: HBED-CC
Inclusion
  • Participate in CXCR4 PET/MRI imaging within 15 days before surgery;
  • The patient voluntarily participates and signs the informed consent form.
  • Surgical resection of glioma lesion tissue can be used for pathological analysis;
  • The patient is at least 18 years old;
  • 1. Patients diagnosed with primary glioma based on clinical, imaging, and histopathological criteria;
Exclusion
  • Patients who are allergic to radioactive tracers and MRI contrast agents, and patients with renal insufficiency.
  • 1. Pregnant or breastfeeding patients;
  • Molecular typing was not determined by histologic examination;
  • patients with claustrophobia;
  • The image quality of the imaging is poor and cannot be used for diagnosis and evaluation;